Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.

被引：0

作者：

Chang, Zhiwei ^{[1
]}

Liu, Xiao-Lei ^{[1
]}

Yu, Dan-Dan ^{[1
]}

Han, Hui-Qiong ^{[1
]}

He, Jian ^{[1
]}

Wang, Rui-Rui ^{[1
]}

Jia, Yong-Xu ^{[1
]}

Yan, Jie ^{[1
]}

Qin, Yanru ^{[1
]}

机构：

[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16017

引用

页数：1

共 50 条

[41] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
Zhang, Changgong
Chen, Jianhua
Wu, Huijuan
Wang, Jun
Gao, Liying
Zhao, Jun
Sun, Yan
Jia, Zhongyao
Mu, Xinlin
Bai, Chunmei
Wang, Rui
Wu, Kailiang
Liu, Qiang
Shi, Yuankai
CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275
[42] Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial
Huang, W.
Han, D.
Li, B.
Dong, J.
ANNALS OF ONCOLOGY, 2024, 35 : S902 - S902
[43] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study
Gui, Lin
Chen, Xinrui
Xie, Zucheng
He, Xiaohui
Yang, Jianliang
Liu, Peng
Qin, Yan
Shi, Yuankai
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial
Chen, Yueyun
Yuan, Yong
Yang, Yu-Shang
Lin, Zhen
Tian, Jiangfang
Liu, Ting
Yue, Zheng
Shi, Hua-Shan
Hu, Yang
Ding, Zhen-Yu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
Shui, Lin
Cheng, Ke
Li, Xiaofen
Shui, Pixian
Zhou, Xiaohan
Li, Jian
Yi, Cheng
Cao, Dan
BMC CANCER, 2020, 20 (01)
[46] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
Lin Shui
Ke Cheng
Xiaofen Li
Pixian Shui
Xiaohan Zhou
Jian Li
Cheng Yi
Dan Cao
BMC Cancer, 20
[47] A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.
Wang, Feng
Xia, Jin
Meng, Xiangrui
Ji, Yinghua
Yang, Xiuli
Hong, Yong-Gui
Wang, Junsheng
Cui, Donghai
Luo, Zhiquan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
Negrier, Sylvie
Rioux-Leclercq, Nathalie
Ferlay, Celine
Gross-Goupil, Marine
Gravis, Gwenaelle
Geoffrois, Lionel
Chevreau, Christine
Boyle, Helen
Rolland, Frederic
Blanc, Ellen
Ravaud, Alain
Dermeche, Slimane
Flechon, Aude
Albiges, Laurence
Perol, David
Escudier, Bernard
EUROPEAN JOURNAL OF CANCER, 2020, 129 : 107 - 116
[49] Camrelizumab combined with albumin paclitaxel and platinum in perioperative treatment of resectable squamous cell lung cancer: A single-arm, open-label, phase II clinical trial
Zhang, Y.
Liu, S.
Yang, L.
Liu, Y.
Wang, C.
Han, Y.
Xiao, B.
Yan, D.
Gong, C.
Wang, F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S978 - S978
[50] Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.
Wang, Zhen
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →